A lawyer by training, she has been a mediator at Canadian Human Rights Tribunal
Marjorie Michel, Canada’s health minister, congratulated Anie Perrault on her appointment as the new chairperson of the Patented Medicine Prices Review Board (PMPRB) until Aug. 9, 2028.
“Her knowledge and leadership were critical in helping the Board finalize its new Guidelines to monitor and review drug prices,” Michel said in a news release from Health Canada.
A lawyer by training, Perrault has been a PMPRB member as well as its vice chairperson, designated in August 2023. She has over three decades of professional experience spanning the public and private sectors.
“I’m pleased she will continue guiding the Board going forward on its important role in protecting and informing Canadians on the price of patented medicines,” Michel said in the news release.
According to Health Canada, Perrault’s fellow board members – Dr. Emily Reynen, Peter Moreland-Giraldeau, and Sharon Blady – will continue to support her as she assumes her new role.
More on Perrault
Perrault’s LinkedIn page provided more information regarding her professional experience, organizational roles, and educational background.
She worked as a lawyer at Philipps & Vineberg in Montreal. She has been executive director of BIOQuébec in Montreal, president of Anie Perrault Communications Inc., vice president for public affairs and communications at adMare BioInnovations in Montreal, and vice president for communications at Genome Canada in Ottawa.
Perrault has chaired the boards of Ballets Jazz Montréal, QV Studio in Sherbrooke, and Genome Quebec in Montreal. She has also belonged to the boards of the Quebec Association of Pharmacy Owners in Montreal, Accessa in Montreal, Loto-Québec in Montreal, the Université de Sherbrooke, and the Eastern Townships Airport Authority in Bromont.
She has been a member (administrative judge) and a mediator at the Canadian Human Rights Tribunal. She earned her accreditation as a mediator from the Quebec Institute of Mediation and Arbitration in 2018. She obtained her BCL from the University of Ottawa in 1992.
About PMPRB
Established by Parliament in 1987 under the Patent Act, 1985, the PMPRB is an independent quasi-judicial body.
According to Health Canada’s news release, the PMPRB aims to ensure that the prices of patented medicines sold in Canada do not become excessive, advance Canadian consumer interests, and report on trends in pharmaceutical sales, pricing for all medicines, and research and development spending by patentees.
On Jan. 26, the PMPRB’s new guidelines took effect. These guidelines clarify the two-step process for monitoring and reviewing drug prices by comparing them with prices in other countries or similar treatments in Canada.
Health Canada noted that the PMPRB’s staff members may recommend a hearing to Perrault as the board’s new chair if they have concerns regarding a drug's price.
